Blood Reviews
Volume 21, Issue 2 , Pages 73-87 , March 2007

An update on malaria prevention, diagnosis and treatment for the returning traveller

  • Effrossyni Gkrania-Klotsas

      Affiliations

    • Department of Infectious Diseases, Box 25, Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 2QQ, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 1223 245151x3317; fax: +44 1223 763401.
    • ,
  • Andrew M.L. Lever

      Affiliations

    • Department of Medicine, University of Cambridge, Level 5, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK
    • Tel.: +44 1223 330191; fax: +44 1223 763401.

References 

  1. White NJ. Malaria. In:  Cook GC,  Zumla AI editor. Manson’s Tropical Diseases. 21st ed.. W.B. Saunders Company; 2002;p. 1205–1295November
  2. Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW. The global distribution and population at risk of malaria: past, present, and future. Lancet Infect Dis. 2004;4(6):327–336
  3. Newman RD, Parise ME, Barber AM, Steketee RW. Malaria-related deaths among U.S. travellers, 1963–2001. Ann Intern Med. 2004;141(7):547–555
  4. Eliades MJ, et al. Malaria surveillance–United States, 2003. MMWR Surveill Summ. 2005;54(2):25–40
  5. Newman RD, Barber AM, Roberts J, Holtz T, Steketee RW, Parise ME. Malaria surveillance–United States, 1999. MMWR Surveill Summ. 2002;51(1):15–28
  6. Causer LM, Newman RD, Barber AM, et al. Malaria surveillance–United States, 2000. MMWR Surveill Summ. 2002;51(SS05):9–23
  7. Filler S, Causer LM, Newman RD, Barber AM, Roberts JM, MacArthur J, et al. Malaria surveillance–United States, 2001. MMWR Surveill Summ. 2003;52(5):1–14
  8. Shah S, Filler S, Causer LM, Rowe AK, Bloland PB, Barber AM, et al. Malaria surveillance–United States, 2002. MMWR Surveill Summ. 2004;53(1):21–34
  9. Steffen R, Fuchs E, Schildknecht J, Naef U, Funk M, Schlagenhauf P, et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. Lancet. 1993;341(8856):1299–1303
  10. Kain KC, MacPherson DW, Kelton T, Keystone JS, Mendelson J, MacLean JD. Malaria deaths in visitors to Canada and in Canadian travellers: a case series. CMAJ. 2001;164(5):654–659
  11. Harling R, Crook P, Lewthwaite P, Evans M, Schmid ML, Beeching NJ. Burden and cost of imported infections admitted to infectious diseases units in England and Wales in 1998 and 1999. J Infect. 2004;48(2):139–144
  12. Greenwood BM, Bojang K, Whitty CJ, Targett GA. Malaria. Lancet. 2005;365(9469):1487–1498
  13. Rose SR. International travel health guide. 13th ed.. Northampton, MA: Travel Medicine, Inc.; 2002;
  14. Bradley DJ, Bannister B. Health Protection Agency Advisory Committee on Malaria Prevention for UK Travellers. Guidelines for malaria prevention in travellers from the United Kingdom for 2003. Commun Dis Public Health. 2003;6(3):180–199
  15. Angus BJ. Malaria on the World Wide Web. Clin Infect Dis. 2001;33(5):651–661Epub 2001 Jul 30
  16. Health Information for International Travel, 2005–2006, http://www.cdc.gov/travel/yb/.
  17. Molineaux L, Muir DA, Spencer HC, Wernsdorfer WH. The Epidemiology of Malaria and its Measurement. In:  Wernsdorfer WH,  McGregor I editor. Malaria: Principles and Practice of Malariology. Edinburgh: Churchill Livingstone; 1988;p. 999–1090
  18. MacDonald G. The epidemiology and control of malaria (Oxford medical publications). Oxford University Press; 1957;
  19. Over M, Bakote’e B, Velayudhan R, Wilikai P, Graves PM. Impregnated nets or DDT residual spraying? Field effectiveness of malaria prevention techniques in Solomon islands, 1993–1999. Am J Trop Med Hyg. 2004;71(2 Suppl):214–223
  20. D’Alessandro U, Olaleye B, Langerock P, Bennett S, Cham K, Cham B, et al. The Gambian National Impregnated Bed Net Programme: evaluation of effectiveness by means of case-control studies. Trans R Soc Trop Med Hyg. 1997;91(6):638–642
  21. Etang J, Chandre F, Guillet P, Manga L. Reduced bio-efficacy of permethrin EC impregnated bednets against an Anopheles gambiae strain with oxidase-based pyrethroid tolerance. Malar J. 2004;3(1):46
  22. Bell JW, Veltri JC, Page BC. Human Exposures to N, N-diethyl-m-toluamide insect repellents reported to the American Association of Poison Control Centers 1993–1997. Int J Toxicol. 2002;21(5):341–352
  23. Sudakin DL, Trevathan WR. DEET: a review and update of safety and risk in the general population. J Toxicol Clin Toxicol. 2003;41(6):831–839
  24. [No authors listed] Picaridin–a new insect repellent. Med Lett Drugs Ther. 2005;47(1210):46–7.
  25. Robb-Nicholson C. By the way, doctor. DEET makes a mess of my fly fishing gear. I’ve heard there are some new mosquito repellents that don’t contain DEET. Are they any good?. Harv Womens Health Watch. 2005;12(12):8
  26. Baird JK. Effectiveness of antimalarial drugs. N Engl J Med. 2005;352(15):1565–1577
  27. White NJ. The treatment of malaria. N Engl J Med. 1996;335:800–806
  28. Stephen R, Jong EC. Travellers’ and Immigrants’ Health. In:  Guerrant RL,  Walker PH,  Wyler PF editor. Tropical Infectious Diseases: Principles, Pathogens and Practice. Philadelphia: Churchill Livingstone; 1999;p. 108
  29. Weber R, Schlagenhauf P, Amsler L, Steffen R. Knowledge, attitudes and practices of business travellers regarding malaria risk and prevention. J Travel Med. 2003;10(4):219–224
  30. Dondorp AM, Newton PN, Mayxay M, et al. Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop Med Int Health. 2004;9(12):1241–1246
  31. Marra F, Salzman JR, Ensom MH. Atovaquone-proguanil for prophylaxis and treatment of malaria. Ann Pharmacother. 2003;37(9):1266–1275
  32. Karbwang J, White NJ. Clinical pharmacokinetics of mefloquine. Clin Pharmacokinet. 1990;19(4):264–279
  33. Kofoed K, Petersen E. The efficacy of chemoprophylaxis against malaria with chloroquine plus proguanil, mefloquine, and atovaquone plus proguanil in travellers from Denmark. J Travel Med. 2003;10(3):150–154
  34. Strauss R, Pfeifer C. Malaria in Austria 1990–2000. Euro Surveill. 2003;8(4):91–96
  35. Kollaritsch H, Que JU, Kunz C, Wiedermann G, Herzog C, Cryz SJ. Safety and immunogenicity of live oral cholera and typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccine, or yellow fever vaccine. J Infect Dis. 1997;175(4):871–875
  36. Rosen JB, Breman JG. Malaria intermittent preventive treatment in infants, chemoprophylaxis, and childhood vaccinations. Lancet. 2004;363(9418):1386–1388
  37. Rosen JB, Breman JG, Manclark CR, Meade BD, Collins WE, Lobel HO, et al. Malaria chemoprophylaxis and the serologic response to measles and diphtheria-tetanus-whole-cell pertussis vaccines. Malar J. 2005;4(1):53
  38. Baird JK, Fryauff DJ, Hoffman SL. Primaquine for prevention of malaria in travellers. Clin Infect Dis. 2003;37(12):1659–1667Epub 2003 Nov 20
  39. Klement E, Chauveheid MP, Thellier M, Bricaire F, Danis M, Caumes E. Subacute clinical forms of Plasmodium falciparum malaria in travellers receiving Chloroquine-Proguanil prophylaxis. Clin Infect Dis. 2001;33(1):e1–e2Epub 2001 May 23
  40. Warhurst DC, Steele JC, Adagu IS, Craig JC, Cullander C. Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant Plasmodium falciparum, in agreement with its physicochemical properties. J Antimicrob Chemother J Antimicrob Chemother. 2003;52(2):188–193Epub 2003 Jul 1
  41. British National Formulary: Appendix 3, number 50/September 2005. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2005.
  42. Croft AM, Whitehouse DP, Cook GC, Beer MD. Safety evaluation of the drugs available to prevent malaria. Expert Opin Drug Saf. 2002;1(1):19–27
  43. Camus D, Djossou F, Schilthuis HJ, Hogh B, Dutoit E, Malvy D, et al. International Malarone Study Team. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travellers: results of an international, randomized, open-label study. Clin Infect Dis. 2004;38(12):1716–1723Epub 2004 May 27
  44. Taylor WR, White NJ. Antimalarial drug toxicity: a review. Drug Saf. 2004;27(1):25–61
  45. Croft AM, Garner P. Mefloquine for preventing malaria in non-immune adult travellers. Cochrane Database Syst Rev. 2000;(3):CD000138
  46. Fonteyne W, Bauwens A, Jordaens L. Atrial flutter with 1:1 conduction after administration of the antimalarial drugMefloquine. Clin Cardiol. 1996;19(12):967–968
  47. van Riemsdijk MM, Sturkenboom MC, Ditters JM, Tulen JH, Ligthelm RJ, Overbosch D, et al. Low body mass index is associated with an increased risk of neuropsychiatric adverse events and concentration impairment in women on mefloquine. Br J Clin Pharmacol. 2004;57(4):506–512
  48. Phillips-Howard PA, Steffen R, Kerr L, Vanhauwere B, Schildknecht J, Fuchs E, et al. Safety of mefloquine and other antimalarial agents in the first trimester of pregnancy. J Travel Med. 1998;5(3):121–126
  49. Smoak BL, Writer JV, Keep LW, Cowan J, Chantelois JL. The effects of inadvertent exposure of mefloquine chemoprophylaxis on pregnancy outcomes and infants of US Army servicewomen. J Infect Dis. 1997;176(3):831–833
  50. Na-Bangchang K, Manyando C, Ruengweerayut R, Kioy D, Mulenga M, Miller GB, et al. The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. Eur J Clin Pharmacol. 2005;61(8):573–582Epub 2005 Jul 23
  51. Suh KN, Mileno MD. Challenging scenarios in a travel clinic: advising the complex traveler. Infect Dis Clin North Am. 2005;19(1):15–47
  52. Shanks GD, Oloo AJ, Aleman GM, et al. A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria. Clin Infect Dis. 2001;33:1968
  53. Walsh DS, Eamsila C, Sasiprapha T, et al. Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P. falciparum malaria. J Infect Dis. 2004;190:1456
  54. Traebert M, Dumotier B. Antimalarial drugs: QT prolongation and cardiac arrhythmias. Expert Opin Drug Saf. 2005;4(3):421–431
  55. Office for National Statistics. Travel trends: a report on the 2003 International Passenger Survey. 2004.
  56. Hughes C, Tucker R, Bannister B, Bradley DJ. Health Protection Agency Advisory Committee on Malaria Prevention for UK Travellers. Malaria prophylaxis for long-term travellers. Commun Dis Public Health. 2003;6(3):200–208
  57. Greenwood B. Malaria vaccines. Evaluation and implementation. Acta Trop. 2005;95(3):298–304
  58. Snounou G, Gruner AC, Muller-Graf CD, Mazier D, Renia L. The Plasmodium sporozoite survives RTS,S vaccination. Trends Parasitol. 2005;21(10):456–461
  59. Miller KK, Banerji A. Epidemiology of malaria presenting at British Columbia’s Children’s Hospital, 1984-2001: lessons for prevention. Can J Public Health. 2004;95(4):245–248
  60. Jain SK, Persaud D, Perl TM, et al. Nosocomial malaria and saline flush. Emerg Infect Dis. 2005;11(7):1097–1099
  61. Moro ML, Romi R, Severini C, Casadio GP, Sarta G, Tampieri G, et al. Malaria Outbreak Group. Patient-to-patient transmission of nosocomial malaria in Italy. Infect Control Hosp Epidemiol. 2002;23(6):338–341
  62. Microscopic procedures for diagnosing malaria. Appendix. MMWR Surveillance Summaries. June 3, 2005 / 54(SS02);39–40.
  63. Durrheim DN, Becker PJ, Billinghurst K. Diagnostic disagreement–the lessons learnt from malaria diagnosis in Mpumalanga. S Afr Med J. 1997;87(8):1016
  64. Kain KC, Harrington MA, Tennyson S, Keystone JS. Imported malaria: prospective analysis of problems in diagnosis and management. Clin Infect Dis. 1998;27(1):142–149
  65. Leder K, Weller P. Epidemiology, pathogenesis, clinical features, and diagnosis of malaria, Version 13.3, August 2005, in Uptodate®.
  66. Lema OE, Carter JY, Nagelkerke N, Wangai MW, Kitenge P, Gikunda SM, et al. Comparison of five methods of malaria detection in the outpatient setting. Am J Trop Med Hyg. 1999;60(2):177–182
  67. Swan H, Sloan L, Muyombwe A, Chavalitshewinkoon-Petmitr P, Krudsood S, Leowattana W, et al. Evaluation of a real-time polymerase chain reaction assay for the diagnosis of malaria in patients from Thailand. Am J Trop Med Hyg. 2005;73(5):850–854
  68. Mangold KA, Manson RU, Koay ES, Stephens L, Regner M, Thomson RB, et al. Real-time PCR for detection and identification of Plasmodium spp. J Clin Microbiol. 2005;43(5):2435–2440
  69. Ciceron L, Jaureguiberry G, Gay F, Danis M. Development of a Plasmodium PCR for monitoring efficacy of antimalarial treatment. J Clin Microbiol. 1999;37(1):35–38
  70. Moody AH, Chiodini PL. Non-microscopic method for malaria diagnosis using OptiMAL IT, a second-generation dipstick for malaria pLDH antigen detection. Br J Biomed Sci. 2002;59(4):228–231
  71. Forney JR, Wongsrichanalai C, Magill AJ, et al. Devices for rapid diagnosis of Malaria: evaluation of prototype assays that detect Plasmodium falciparum histidine-rich protein 2 and a Plasmodium vivax-specific antigen. J Clin Microbiol. 2003;41(6):2358–2366
  72. Murray CK, Bell D, Gasser RA, Wongsrichanalai C. Rapid diagnostic testing for malaria. Trop Med Int Health. 2003;8(10):876–883
  73. Hanscheid T. Diagnosis of malaria: a review of alternatives to conventional microscopy. Clin Lab Haematol. 1999;21(4):235–245
  74. Wongsrichanalai C. Rapid diagnostic techniques for malaria control. Trends Parasitol. 2001;17(7):307–309
  75. Moody A. Rapid diagnostic tests for malaria parasites. Clin Microbiol Rev. 2002;15(1):66–78
  76. Marx A, Pewsner D, Egger M, Nuesch R, Bucher HC, Genton B, et al. Meta-analysis: accuracy of rapid tests for malaria in travellers returning from endemic areas. Ann Intern Med. 2005;142(10):836–846
  77. Wever PC, Henskens YM, Kager PA, Dankert J, van Gool T. Detection of imported malaria with the Cell-Dyn 4000 hematology analyzer. J Clin Microbiol. 2002;40(12):4729–4731
  78. Svenson JE, MacLean JD, Gyorkos TW, Keystone J. Imported malaria. Clinical presentation and examination of symptomatic travellers. Arch Intern Med. 1995;155(8):861–868
  79. White NJ. Antimalarial Drug Resistance. J Clin Invest. 2004;113(8):1084–1092
  80. Badiaga S, Brouqui P, Carpentier JP, Hovette P, Duigou F, Manelli JC, et al. Severe imported malaria: Clinical presentation at the time of hospital admission and outcome in 42 cases diagnosed from 1996 to 2002. J Emerg Med. 2005;29(4):375–382
  81. Antinori S, Galimberti L, Gianelli E, Calattini S, Piazza M, Morelli P, et al. Prospective observational study of fever in hospitalized returning travellers and migrants from tropical areas, 1997–2001. J Travel Med. 2004;11(3):135–142
  82. Drugs for Parasitic Infections, The Medical Letter on Drugs and Therapeutics, August 2004, http://www.medletter.com/freedocs/parasitic.pdf.
  83. Woodrow CJ, Haynes RK, Krishna S. Artemisinins. Postgrad Med J. 2005;81(952):71–78
  84. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. Lancet Infect Dis. 2002;2(4):209–218
  85. Looareesuwan S, Chulay JD, Canfield CJ, Hutchinson DB. Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group. Am J Trop Med Hyg. 1999;60(4):533–541
  86. Looareesuwan S, Wilairatana P, Chalermarut K, Rattanapong Y, Canfield CJ, Hutchinson DB. Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg. 1999;60(4):526–532
  87. ter Kuile F, White NJ, Holloway P, Pasvol G, Krishna S. Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. Exp Parasitol. 1993;76:85–95
  88. Toovey S, Jamieson A. Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether. Trans R Soc Trop Med Hyg. 2004;98(5):261–267discussion 268–9
  89. Looareesuwan S, Viravan C, Vanijanonta S, Wilairatana P, Suntharasamai P, Charoenlarp P, et al. Randomised trial of artesunate and mefloquine alone and in sequence for acute uncomplicated falciparum malaria. Lancet. 1992;339(8797):821–824
  90. Campbell P, Baruah S, Narain K, Rogers CC. A randomized trial comparing the efficacy of four treatment regimens for uncomplicated falciparum malaria in Assam state, India. Trans R Soc Trop Med Hyg. 2005;(11):[Epub ahead of print]
  91. Omari A, Gamble C, Garner P, Omari A. Artemether-lumefantrine (six-dose regimen) for treating uncomplicated falciparum malaria. Cochrane Database Syst Rev. 2005;(4):CD005564
  92. Dondorp A, Nosten F, Stepniewska K, Day N, White N. South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet. 2005;366(9487):717–725
  93. Bukirwa H, Orton L, Bukirwa H. Artesunate plus mefloquine versus mefloquine for treating uncomplicated malaria. Cochrane Database Syst Rev. 2005;(4):CD004531
  94. Sumawinata IW, Bernadeta B Leksana, Sutamihardja A, Purnomo B Subianto, Sekartuti DJ Fryauff, Baird JK. Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. Am J Trop Med Hyg. 2003;68(4):416–420
  95. Tjitra E, Baker J, Suprianto S, Cheng Q, Anstey NM. Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Antimicrob Agents Chemother. 2002;46(12):3947–3953
  96. Myat-Phone-Kyaw , Myint-Oo , Aung-Naing , Aye-Lwin-Htwe . The use of primaquine in malaria infected patients with red cell glucose-6-phosphate dehydrogenase (G6PD) deficiency in Myanmar. Southeast Asian J Trop Med Public Health. 1994;25(4):710–713
  97. Shulman CE, Dorman EK. Importance and prevention of malaria in pregnancy. Trans R Soc Trop Med Hyg. 2003;97(1):30–35
  98. Orton L, Garner P. Drugs for treating uncomplicated malaria in pregnant women. Cochrane Database Syst Rev. 2005;(3):CD004912
  99. Adam I, Mirghani OA, Saed OK, et al. Quinine therapy in severe Plasmodium falciparum malaria during pregnancy in Sudan. East Mediterr Health J. 2004;10(1–2):159–166
  100. Nosten F, Vincenti M, Simpson J, Yei P, Thwai KL, de Vries A, et al. The effects of mefloquine treatment in pregnancy. Clin Infect Dis. 1999;28(4):808–815
  101. WHO . Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans R Soc Trop Med Hyg. 2000;94(Suppl 1):S1–S90
  102. Geoffrey Pasvol. Malaria. In: Cohen & Powderly, Infectious Diseases, 2nd ed.Mosby. 2004.
  103. Hien TT, Phu NH, Mai NT, Chau TT, Trang TT, Loc PP, et al. An open randomized comparison of intravenous and intramuscular artesunate in severe falciparum malaria. Trans R Soc Trop Med Hyg. 1992;86(6):584–585
  104. Hien TT, Arnold K, Vinh H, Cuong BM, Phu NH, Chau TT, et al. Comparison of artemisinin suppositories with intravenous artesunate and intravenous quinine in the treatment of cerebral malaria. Trans R Soc Trop Med Hyg. 1992;86(6):582–583
  105. Tran TH, Day NP, Nguyen HP, Nguyen TH, Tran TH, Pham PL, et al. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med. 1996;335(2):76–83
  106. Ashley EA, White NJ. Artemisinin-based combinations. Curr Opin Infect Dis. 2005;18(6):531–536
  107. Aceng JR, Byarugaba JS, Tumwine JK. Rectal artemether versus intravenous quinine for the treatment of cerebral malaria in children in Uganda: randomised clinical trial. BMJ. 2005;330(7487):334
  108. Olliaro PL, Taylor WR. Developing artemisinin based drug combinations for the treatment of drug resistant falciparum malaria: A review. J Postgrad Med. 2004;50(1):40–44

PII: S0268-960X(06)00028-2

doi: 10.1016/j.blre.2006.03.004

Blood Reviews
Volume 21, Issue 2 , Pages 73-87 , March 2007

Article Tools

* Image Usage & Resolution